A cup of coffee with … Debby Kruijsen (ModiQuest Research)
Debby Kruijsen began her career in antibody discovery in 2011 when she obtained a PhD in immunology at the University of Utrecht, The Netherlands, studying the role of antibodies in affecting antigen presentation and subsequent Respiratory Syncytial Virus specific T cell activation.
Read more
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
— Plan to evaluate Forty Seven’s CD47 antibody in combination with rituximab and Calquence (acalabrutinib) — — Novel combination aims...
Read more
Calquence Phase III ASCEND trial met primary endpoint at interim analysis in relapsed or refractory chronic lymphocytic leukaemia and will stop early
AstraZeneca today announced positive results from the Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL)....
Read more
New at Pivot Park – DPS
Recently the DPS Group opened the doors of its offices at Pivot Park. DPS Group is a global consulting, engineering...
Read more
We need to look for new ways to translate basic research into healthcare
Saman Honarnejad studied biotechnology in Germany and the United States. For several years he has been project manager at Pivot Park Screening Centre (PPSC). PPSC screens candidate drugs through automated processes, enabling very large number of parallel experimentation. Honarnejad is in charge of COILED drug discovery program at PPSC, a joint effort between various academic institutions and biotechnology companies that is stimulating the discovery of new drug candidates. He is an advocate of open innovation, enabling translation of new insights from basic research in industry
Read more
The European Lead Factory, Europe’s largest collaborative drug discovery platform, continues its success story
The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in the new project ESCulab (European Screening Centre: unique library for attractive biology) under the European Lead Factory brand.
Read more
New at Pivot Park – Cytura Therapeutics
Recently Cytura Therapeutics opened the doors to its laboratory at Pivot Park. Cytura Therapeutics is focused on Developing a new class of drugs targeting genomic instability in cancer. Cytura Therapeutics is founded by Dr Ad van Gorp, former CEO of Lead Pharma, the Centre for Drug Design and Discovery (CD3) of the KU Leuven and Amsterdam UMC.
Read more
Voucher gives rise to collaboration
Synaffix has developed a new technology for targeted anti-cancer therapy. Specifically, Synaffix has improved the therapeutic window of an antibody-drug...
Read more
Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen
Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the...
Read more